ChemicalBook > CAS DataBase List > Zolmitriptan

Zolmitriptan

Product Name
Zolmitriptan
CAS No.
139264-17-8
Chemical Name
Zolmitriptan
Synonyms
Zomig;Zomi;311c90;bw311c90;Zolmitrptan;zolmitripan;Zolmitriptan;ZOLMITRIPTANE;ZOLIMITRIPTAN;Zuomi quputan
CBNumber
CB3313219
Molecular Formula
C16H21N3O2
Formula Weight
287.36
MOL File
139264-17-8.mol
More
Less

Zolmitriptan Property

Melting point:
136-141°C
alpha 
D22 -5.79° (c = 0.5 in methanol)
Boiling point:
563.3±38.0 °C(Predicted)
Density 
1.217±0.06 g/cm3(Predicted)
storage temp. 
15-25°C
solubility 
Soluble in DMSO at 5mg/ml
pka
9.64(at 25℃)
form 
powder
color 
white to beige
optical activity
[α]/D -3 to -8°, c = 1 in methanol
λmax
225nm(lit.)
Merck 
14,10189
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
CAS DataBase Reference
139264-17-8(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xi,Xn
Risk Statements 
36/37/38-22
Safety Statements 
26-36
WGK Germany 
3
RTECS 
RQ2707000
HS Code 
29349990
Toxicity
women,TDLo,oral,6mg/kg/43W-I (6mg/kg),BEHAVIORAL: HEADACHE,Lancet. Vol. 353, Pg. 378, 1999.
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML0248
Product name
Zolmitriptan
Purity
≥98% (HPLC)
Packaging
10mg
Price
$107
Updated
2024/03/01
Sigma-Aldrich
Product number
1727009
Product name
Zolmitriptan
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$436
Updated
2024/03/01
TCI Chemical
Product number
Z0024
Product name
Zolmitriptan
Purity
>98.0%(HPLC)(T)
Packaging
1g
Price
$311
Updated
2024/03/01
TCI Chemical
Product number
Z0024
Product name
Zolmitriptan
Purity
>98.0%(HPLC)(T)
Packaging
200mg
Price
$89
Updated
2024/03/01
Alfa Aesar
Product number
J60616
Product name
Zolmitriptan
Packaging
1g
Price
$418
Updated
2023/06/20
More
Less

Zolmitriptan Chemical Properties,Usage,Production

Description

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is mainly used in the acute treatment of migraine attacks with or without aura and cluster headaches. Zolmitriptan takes effect through binding to human 5-HT1Band 5-HT1Dreceptors, leading to cranial blood vessel constriction and the release of sensory neuropeptides through nerve endings in the trigeminal system.

Chemical Properties

White Crystalline Powder

Originator

Zeneca (UK)

Uses

adrenergic agonist, nasal decongestant

Uses

Zolmitriptan is a serotonin 5HTID-receptor agonist and used to treat migraine (1,2,3).

Definition

ChEBI: Zolmitriptan is a member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is a member of tryptamines and an oxazolidinone. It is functionally related to a N,N-dimethyltryptamine.

Manufacturing Process

(S)-4-(4-[N'-(2-Oxotetrahydropyran-3-iliden)hidrazino]benzyl}-1,3-oxazolidin- 2-one
A solution of 2.8 g (40.6 mmoles) of sodium nitrite in 12 ml of water was added slowly to a solution of 9.1 g (39.8 mmoles) of (S)-4-(4-aminobenzyl)- 1,3-oxazolidyne-2-one hydrochloride in 17 ml of water and 29 ml of concentrated HCl, keeping the reaction temperature below 0°C. The mixture was stirred at this temperature for 15 minutes. Once that time had elapsed the diazonium salt solution was added rapidly to a suspension of 30 g (239 mmoles) of sodium sulphite in 106 ml of water precooled to 0°C under nitrogen atmosphere. The red solution was stirred at 0°C for 10 minutes and then left to reach 65°C in 1 hour. It was stirred at 65°C for 30 minutes, and 18.2 ml of concentrated HCl then added. The mixture was stirred at the same temperature under nitrogen atmosphere for 3 hours and then left to cool to room temperature. To this solution was added a solution of 35 mmoles of α- keto-γ-valerolactone (prepared by decarboxylation of 11.8 g (63.7 mmoles) of a ethoxyalyl-γ-butyrolactone in 15.2 ml of 2 N H 2 SO 4 at reflux) and left under stirring at room temperature for 12 hours. When that time had elapsed the mixture was cooled to 0°C and stirred for one hour. The precipitate formed was filtered, washed with cold water and dried in an hotair oven at 40°C, giving a white solid which was crystallised from ethanol/water to give 10.5 g (87%) of the title hydrazone as a white solid. Melting point 223.3°-224.7°C.
(S)-6-(2-Oxo-1,3-oxazolidin-4-ylmethyl)-4,9-dihydro-3H-pyrano-[3,4-b]indol- 1-one
3.8 g (12.5 mmoles) of (S)-4-{4-[N'-(2-oxotetrahydropyran-3-iliden) hydrazino]benzyl}-1,3-oxazolidin-2-one were suspended in 32 ml of a saturated solution of hydrogen chloride in acetic acid. The mixture was stirred at room temperature for 16 h, 10 ml of water/ice was added to the reaction mixture and stirred at 0°C for 20 min. The precipitate was filtered, washed with cold water and dried in hot-air oven at 40°C. The residue was crystallised with methanol to yield 3.3 g (92%) of the title indole as a yellow crystalline solid. Melting point 215°-217°C.
(S)-3-(2-Hydroxyethyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1-H-indol-2- carboxylicacid methyl ester
To a suspension of 500 mg (1.74 mmoles) of the (S)-6-(2-oxo-1,3-oxazolidin- 4-ylmethyl)-4,9-dihydro-3-pyrano-[3,4-b]indol-1-one in 10 ml of methanol were added 0.12 ml (1.9 mmoles) of methanesulfonic acid. The mixture was left under stirring at the reflux temperature for 3 hours. The solvent was evaporated to dryness under reduced pressure, the residue dissolved with 10 ml of a saturated bicarbonate solution and extracted three times with dichloromethane. The combined organic phases were dried and evaporated to dryness and the evaporated solid recrystallised from ethanol to give 517 mg (93%) of the title ester as a yellow crystalline solid. Melting point 178°- 180°C.
(S)-3-(2-Hydroxyethyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-2- carboxylicacid ethyl ester
9.5 g (31.3 mmoles) of (S)-4-{4-[N'-(2-oxotetrahydropyran-3-ilyden) hydrazine]benzyl}-1,3-oxazolidin-2-one were suspended in 76 ml of a 2 N solution of hydrogen chloride in absolute ethanol. The mixture was left under stirring at 75°C for 30 min. The solvent was evaporated to dryness under reduced pressure, 50 ml of a saturated solution of potassium carbonate added, and then extracted three times with 50 ml of dichloromethane. The combined organic phases were dried on anhydrous sodium sulphate and recrystallised from methanol to give a yellow crystalline solid. Melting point 154°-156°C. evaporated to dryness. The residue was recrystallised from isopropyl alcohol/heptane to give 9.25 g (89%) of the title indole. The product was

brand name

Zomig (AstraZeneca); Zomig (IPR).

Therapeutic Function

Serotoninergic

General Description

Zolmitriptan, the second triptan marketed (approved in1997), has a much better bioavailability (40%–48%) thansumatriptan. It is rapidly absorbed after oral or nasal sprayadministration. It also has an orally disintegrating tablet formulation(Zomig ZMT), which can be taken without water.Zolmitriptan undergoes rapid N-demethylation via CYP1A2to a more potent, active metabolite, N-desmethylzolmitriptan,which is 2 to 6 times more potent than the parentdrug. This active metabolite was detected 5 minutesafter dosing and accounts for about two thirds of the plasmaconcentration of the administered dose of the parent drug.284Thus, it is reasonable to assume that the therapeutic effectsand especially the CNS side effects of zolmitriptan must bein part attributed to the plasma levels of this active metabolite,at least until it is further degraded by hepatic MAO-Ato its inactive indole acetic acid derivatives.

Biochem/physiol Actions

Zolmitriptan is a selective serotonin receptor agonist of the 5HT1B and 5HT1D subtypes, both centrally and peripherally. It has been used clinically for the acute treatment of migraine attacks with or without aura and cluster headaches.

Clinical Use

Zomig was launched in Germany, Denmark, Sweden and the UK for use as an antimigraine agent (with and without aura). It can be prepared by three related routes of 5 to 7 steps starting from L-4-nitrophenylalanine. Zomig is a 5-HT1D/1B receptor agonist (10 fold ratio) with modest (< 100x) affinity for 5-HT1A and 5-HT1F receptors. It has no affinity for other serotonin receptors or receptors of other neurotransmitters. It has a novel dual action mechanism: centrally it acts on the trigeminal nucleus caudalis and peripherally is acts on the trigeminovascular system. Zomig was effective in treating headaches and nonheadache (photophobia, phonophobia and nausea) symptoms. It was 2-3 times more potent than sumatriptan and is metabolized to three compounds, one of which is 2-8 times more active than the parent. It caused a 40-50% decrease in headache after 1 h and a 73-77% after 4 h. There was a 30% reoccurance of headache but 90% effective treatment with a second dose. It blocks neurogenic inflammation by inhibiting release of peptides, causes vasoconstriction, and inhibits neuronal depolarization at peripheral sites in the cranium. It is 40% bioavailable and a 10 time theraputic dose showed no safety concerns.

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: quinolones possibly inhibit metabolism - reduce dose of zolmitriptan.
Antidepressants: increased risk of CNS toxicity with citalopram - avoid; risk of CNS toxicity with MAOIs and moclobemide - reduce dose of zolmitriptan to max 7.5 mg; SSRIs inhibit metabolism of zolmitriptan, reduce dose with fluvoxamine; possibly increased serotonergic effects with duloxetine and venlafaxine; increased serotonergic effects with St John’s wort - avoid concomitant use.
Cimetidine: inhibits metabolism of zolmitriptan; maximum dose is 5 mg.
Dapoxetine: possible increased risk of serotonergic effects - avoid for 2 weeks after stopping 5HT1 agonists.
Ergot alkaloids: increased risk of vasospasm.
Linezolid: risk of CNS toxicity - reduce dose of zolmitriptan.

Metabolism

Zolmitriptan is eliminated largely by hepatic biotransformation followed by urinary excretion of the metabolites. There are three major metabolites: the indole acetic acid, (the major metabolite in plasma and urine), the N-oxide and N-desmethyl analogues. Only the N-desmethylated metabolite is active. The primary metabolism of zolmitriptan is mediated mainly by the cytochrome P450 isoenzyme CYP1A2 while monoamine oxidase type A is responsible for further metabolism of the N-desmethyl metabolite. Over 60
% of a dose is excreted in the urine, mainly as the indole acetic acid, and about 30
% appears in the faeces, mainly as unchanged drug.

storage

+4°C

References

https://www.drugbank.ca/drugs/DB00315
Rothner, A. D., et al. "Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents." Headache the Journal of Head & Face Pain 46.1(2006):101.
Hedlund, C, et al. "Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. " Neurology49.9(2009):1315–1323.

Zolmitriptan Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Zolmitriptan Suppliers

Nanjing Tengyi Biotechnology Co., Ltd
Tel
025-58851786 17714337195
Email
sales@tybiochem.com
Country
China
ProdList
7413
Advantage
58
Wuhan EnTai Technology Development Co,.Ltd
Tel
86-27-82330560
Fax
86-27-82330547
Email
2536851935@qq.com
Country
China
ProdList
347
Advantage
69
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chemvon Biotechnology Co., Ltd
Tel
021-50790412
Fax
+86-21-50790419
Email
info@chemvon.com
Country
China
ProdList
371
Advantage
57
ZHIWE CHEMTECH CO LTD
Tel
021-20221225 13917446399
Fax
QQ:115820162
Email
sales@zhiwe.net
Country
China
ProdList
604
Advantage
61
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
TAIYUAN RHF CO.,LTD.
Tel
+86 351 7031519
Fax
+86 351 7031519
Email
sales@RHFChem.com
Country
China
ProdList
2338
Advantage
56
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24529
Advantage
81
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44689
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35896
Advantage
56
More
Less

View Lastest Price from Zolmitriptan manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Zolmitriptan 139264-17-8
Price
US $0.00/g
Min. Order
1g
Purity
98.0%
Supply Ability
1kg/month
Release date
2021-07-23
Hebei Zhuanglai Chemical Trading Co.,Ltd
Product
Zolmitriptan 139264-17-8
Price
US $120.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20ton
Release date
2024-04-24
Sinoway Industrial co., ltd.
Product
Zolmitriptan 139264-17-8
Price
US $0.00-0.00/Kg/Bag
Min. Order
1Kg/Bag
Purity
0.99
Supply Ability
20 tons
Release date
2024-06-27

139264-17-8, ZolmitriptanRelated Search:


  • ZOLMITRIPTANE
  • (4r)-4-[[3-(2-dimethylaminoethyl)-1h-indol-5-yl]methyl]oxazolidin-2-one
  • Zolmitriptan
  • Assists Mi Qu Pu Tanzania
  • Zolmitriptan (150 mg)
  • (4R)-4-({3-[2-(diMethylaMino)ethyl]-1H-indol-5-yl}Methyl)-1,3-oxazolidin-2-one
  • ZolMitriptan(ZoMig)
  • ZolMitriptan API
  • ZOLIMITRIPTAN
  • (R)-4-((3-(2-(diMethylaMino)ethyl)-1H-indol-5-yl)Methyl)oxazolidin-2-one
  • Zolmitriptan, 98%, a selective 5-HT1B/1D/1F receptor agonist
  • Zolmitriptan (4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
  • (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone
  • (s)-2-oxazolidinon
  • (s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-2-oxazolidinone
  • 311c90
  • bw311c90
  • Zolmitrptan
  • (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinone
  • Zomi
  • (S)-4-[3-(2-DIMETHYLAMINO-ETHYL)-1H-INDOL-5-YLMETHYL]-OXAZOLIDIN-2-ONE
  • (S)-4-(4-hydrazinobenzyl)-2-oxazolidinone(S)-4-(4-aminobenzyl)-2-oxazolidinone4-(2-Dimethylamino) butyaldehyde diethyl acetal
  • Zomig
  • zolmitripan
  • (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-
  • Zolmitriptan CRS
  • 2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-, (4S)-
  • Zolmitriptan for system suitability
  • Zolmitriptan USP/EP/BP
  • ZolmitriptanQ: What is Zolmitriptan Q: What is the CAS Number of Zolmitriptan Q: What is the storage condition of Zolmitriptan Q: What are the applications of Zolmitriptan
  • Zolmitriptan APIs
  • Zolmitriptan (1727009)
  • 1,4-Benzenediamine,2,11-dibromo-
  • Zuomi quputan
  • Zolmitriptan Standard
  • (4S)-4-[[3-[2- (Dimethylamino) ethyl]-1H- indol-5-yl] methyl]-2- oxazolidinone, usp
  • 139264-17-8
  • 13924-17-8
  • C16H15NO2D6
  • C16H21N3O2
  • ALBALON
  • Other APIs
  • All Inhibitors
  • Antimigraine
  • ZOLMITRIPTAN
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API
  • 139264-17-8